Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.’s Annual Virtual Healthcare Conference on May 20. These events provide an opportunity for Tonix to showcase its recent commercial and pipeline advancements to the investment community.
Tonix recently achieved a significant milestone with the approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is now leveraging its central nervous system (CNS) commercial infrastructure to support TONMYA, alongside its acute migraine products Zembrace® SymTouch® and Tosymra®. Beyond fibromyalgia, Tonix is exploring TONMYA’s potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The CNS pipeline also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder.
In immunology, Tonix is advancing monoclonal antibody programs: TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs address high unmet medical needs in infectious disease and transplant medicine. The company’s participation in the upcoming conferences signals its commitment to updating stakeholders on its progress and strategy.
For investors, these presentations offer insights into Tonix’s commercial execution and pipeline progress. The company’s focus on CNS and immunology positions it in two high-growth therapeutic areas. With TONMYA now on the market, Tonix has a revenue-generating product that could drive near-term financial performance, while its pipeline offers long-term growth potential. The conferences also provide an opportunity for management to address questions on commercialization and clinical development timelines.
More information about Tonix Pharmaceuticals is available in the company’s newsroom at https://ibn.fm/TNXP. The full press release regarding the conference participation can be viewed at https://ibn.fm/ZZpG2.
